Regulatory T Cells Contribute to the Inhibition of Radiation-Induced Acute Lung Inflammation via Bee Venom Phospholipase A2 in Mice

Dasom Shin 1,†, Gihyun Lee 1,†, Sung-Hwa Sohn 2, Soojin Park 1, Kyung-Hwa Jung 1, Ji Min Lee 2, Jieun Yang 1, Jaeho Cho 2,* and Hyunsu Bae 1,*

1 Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 130-701, South Korea; ssd060@naver.com (D.S.); glee@khu.ac.kr (G.L.); ih_sj@naver.com (S.P.); jhh242@naver.com (K.-H.J.); yje2020@hanmail.net (J.Y.)
2 Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 120-752, South Korea; 19980769@hanmail.net (S.-H.S.); carol114@yuhs.ac (J.M.L.)
* Correspondence: jjhmd@yuhs.ac (J.C.); hbae@khu.ac.kr (H.B.); Tel.: +82-2-2228-8095 (J.C.);
+82-2-961-9316 (H.B.)
† These authors contributed equally to this work.

Abstract: Bee venom has long been used to treat various inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis. Previously, we reported that bee venom phospholipase A2 (bvPLA2) has an anti-inflammatory effect through the induction of regulatory T cells. Radiotherapy is a common anti-cancer method, but often causes adverse effects, such as inflammation. This study was conducted to evaluate the protective effects of bvPLA2 in radiation-induced acute lung inflammation. Mice were focally irradiated with 75 Gy of X-rays in the lung and administered bvPLA2 six times after radiation. To evaluate the level of inflammation, the number of immune cells, mRNA level of inflammatory cytokine, and histological changes in the lung were measured. BvPLA2 treatment reduced the accumulation of immune cells, such as macrophages, neutrophils, lymphocytes, and eosinophils. In addition, bvPLA2 treatment decreased inflammasome-, chemokine-, cytokine- and fibrosis-related genes’ mRNA expression. The histological results also demonstrated the attenuating effect of bvPLA2 on radiation-induced lung inflammation. Furthermore, regulatory T cell depletion abolished the therapeutic effects of bvPLA2 in radiation-induced pneumonitis, implicating the anti-inflammatory effects of bvPLA2 are dependent upon regulatory T cells. These results support the therapeutic potential of bvPLA2 in radiation pneumonitis and fibrosis treatments.

Keywords: bee venom; phospholipase A2; inflammation; radiotherapy; regulatory T cells

1. Introduction

Bee venom (apitoxin) has long been used in alternative medicine to treat various diseases, such as rheumatoid arthritis, asthma, cancer, and neurodegenerative diseases, and possesses strong immune modulatory effects [1–6]. The therapeutic effect of bee venom is associated with its anti-inflammatory, anti-cancer, and anti-nociceptive activity. Bee venom consists of phospholipase A2 (bvPLA2), melittin, adolapin, apamin, and mast cell degranulating peptide [7]. BvPLA2 has been considered as a major allergenic compound of bee venom; however, new experimental data has shown the protective immune responses of bvPLA2 against a wide range of diseases, including inflammatory disorders [8].
Radiotherapy (Irradiation; IR) is a treatment involving the use of high-energy radiation, commonly used to treat cancer. It can also be used prior to surgery to shrink a tumor so that it is easier to remove, or post-surgery to destroy small amounts of tumor that may be left. Stereotactic body radiotherapy (SBRT) delivers a higher dose of radiation with improved accuracy, compared to conventional radiotherapy, and many SBRT studies in lung cancer have reported excellent results [9,10]. Nevertheless, the adverse effects of radiation on normal tissues that surround the tumor often preclude the application of curative radiation doses. These radiation-induced side effects, which include radiation pneumonitis and late pulmonary fibrosis, are common. In a previous study, it was shown that radiation pneumonitis and late pulmonary fibrosis may involve inflammasomes and an innate immune response to tissue inflammation and injury [11–13]. The innate immune system senses tissue damage and translates the information to other repair and defense systems in the body by stimulating wound repair and angiogenesis, as well as activating adaptive immunity [14]. Inflammasome signaling is followed by IL-1β processing and secretion in dendritic cells, macrophages, and epithelial cells [15–20]. Taken together, these events are associated with concomitant radiation-induced pneumonitis and fibrosis. In this study, we selected a clinical SBRT-treated animal model to better understand the therapeutic effects of bvPLA2 on radiation pneumonitis.

Our recent studies demonstrated that bee venom PLA2 possesses a strong capability to increase the population of regulatory T cells (Tregs) [21,22]. Tregs are potent immune modulatory cells and maintain tolerance toward autoantigens, and are also key immune suppressors for preventing overwhelming immune responses. Notably, bvPLA2 induced Tregs and caused immunosuppressive effects via Tregs in the lungs [23]. Based on these previous results, we hypothesized that bvPLA2 might be able to alleviate radiation-induced pneumonitis, mediated by Treg induction. In this study, we provide strong evidence that bvPLA2 has potential therapeutic use to reduce radiation-induced lung inflammation.

2. Results

2.1. The Effect of Bee Venom PLA2 on Histological Changes in Irradiated Lung Tissue

To evaluate the effects of bvPLA2 on radiation-induced lung injury, a single dose of 75 Gy of X-rays was delivered to the left lung in a single fraction. Lung sections stained with H&E revealed that focal irradiation induced the formation of an intra-alveolar hyaline membrane and inflammatory cell infiltration (Figure 1). The alveolar inflammatory score of the IR+PBS group was significantly higher compared with the control (Figure 1C). By contrast, the IR+PLA2 group showed less tissue damage, such as the formation of an intra-alveolar hyaline membrane and inflammatory cell infiltration (Figure 1A). Masson’s trichrome staining revealed that the IR+PBS group showed significant increases in collagen deposition and number of fibrotic foci (Figure 1B,D). Treatment with bvPLA2 significantly reduced collagen deposition (Figure 1B,D).

2.2. The Effect of Bee Venom PLA2 on Pulmonary Inflammation

To elucidate whether bvPLA2 influences immune cell infiltration into the lung in radiation-induced inflammation, BAL fluid mice were evaluated three weeks after treatment with 75 Gy of radiation. A significant increase in the influx of total cells, macrophages, neutrophils, lymphocytes, and eosinophils was observed in the IR+PBS group compared to the control group. The bvPLA2 treatment group exhibited significantly decreased numbers of immune cells, including macrophages, neutrophils, lymphocytes, and eosinophils in BAL fluid, compared with the IR+PBS group (Figure 2).
2.3. The Effects of Bee Venom PLA2 on Inflammation- and Fibrosis-Related Gene Expressions in Irradiated Lung Tissue

Figure 1. Effect of bee venom PLA2 on lung inflammation and lung fibrosis. (A) The lung sections were stained with H&E. Representative images of magnifications (×200) at day 21. (B) The lung sections were stained with Masson's trichrome. Representative images of magnifications (×200) at day 21. (C) Quantification of inflammatory foci. (D) Quantification of fibrotic foci. Data are expressed as the mean ± SEM (** p < 0.01, *** p < 0.001 versus IR+PBS; n = 7–10). CON: non-irradiation, IR+PBS: irradiation + PBS, IR+PLA2: irradiation + bee venom PLA2.

Figure 2. Effect of bee venom PLA2 on immune cell profiles in BAL fluid. The number of total cells (A); macrophages (B); neutrophils (C); lymphocytes (D) and eosinophils (E) were determined in BAL fluid. Data are expressed as the mean number of cells ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001 versus IR+PBS; n = 7–10). CON: non-irradiation, IR+PBS: irradiation + PBS, IR+PLA2: irradiation + bee venom PLA2.
Gene expression profiles in the lung were assessed by real-time PCR. The expression of inflammasome- (Nlrp1, Nlrp3, Il-1b, and Casp1), chemokine- (Mip1a, Mcp1, and CCL4), cytokine- (Il-6 and Il-17c), and fibrosis-related (Col3a1 and Fn1) genes were increased in the IR+PBS group (Figure 3). However, treatment with bvPLA2 significantly reduced inflammasome-, chemokine-, cytokine-, or fibrosis-related genes in lung tissue, compared to the IR + PBS group (Figure 3). We also performed IHC staining for TGF-β1 (Figure 4), because TGF-β plays an important role in the development of radiation pneumonitis and radiation fibrosis [24]. The histological results also demonstrated that the TGF-β1 positive areas of the X-ray irradiated lung were significantly decreased by bvPLA2 treatment (Figure 4B).

**Figure 3.** Effect of bee venom PLA2 on mRNA levels in lung tissue. (A) Nlrp3; (B) Nlrp1; (C) Casp1; (D) Il-1b; (E) Col3a1; (F) Fn1; (G) Il-6; (H) Mip1a; (I) Mcp1; (J) Il-17c; (K) CCL4. Data are expressed as the mean ± SEM (⁎ p < 0.05, ⁎⁎ p < 0.01, ⁎⁎⁎ p < 0.001 versus IR+PBS; n = 7–10). CON: non-irradiation, IR + PBS: irradiation + PBS, IR + PLA2: irradiation + bee venom PLA2.
These results suggest that Tregs, at least in part, contribute to the therapeutic effects of bvPLA2 in radiation-induced lung inflammation. To determine whether Tregs were involved in the effects of bvPLA2 on radiation-induced pneumonitis, mice were injected with the PC61 antibody to deplete Treg in vivo. The efficacy of Treg depletion (≥90%) was confirmed prior to irradiation (Figure 5A). The Treg-depleted model system showed a distinct role for Tregs in the effect of bvPLA2 on immune cell infiltration in lung tissue. BvPLA2 treatment showed an obvious effect on the influx of total cells, macrophages, neutrophils, lymphocytes, and eosinophils into BAL fluid in control IgG antibody injected mice. In anti-CD25 antibody-injected mice, however, bvPLA2 showed a tendency to decrease the number of such infiltrated cells, but this was not statistically significant (Figure 5B). These results suggest that Tregs, at least in part, contribute to the therapeutic effects of bvPLA2 in radiation-induced lung inflammation.

Figure 4. Effect of bee venom PLA2 on TGF-β1 expression in lung tissue. Lung sections were stained with TGF-β1 using immunohistochemistry at day 21 after irradiation. CON: non-irradiation, IR+PBS: irradiation + PBS, IR + PLA2: irradiation + bee venom PLA2. (A) Representative images of magnifications (×200). (B) Quantification of TGF-β1 expression foci, ×200. Randomly selected fields of view for each slide were scored for area and intensity of positively stained (brown) cytoplasm and cell membrane. The intensity scores for positively stained areas were divided into 4 groups: (1) no appreciable staining = 0; (2) barely detectable staining = 1; (3) readily appreciable brown staining = 2; and (4) dark brown staining = 3. The total score was calculated by adding the intensity scores from three independent slides in each sample, resulting in a final score of 0 to 9. For statistical analysis, scores of 3 to 9 were defined as positive expression, while scores of 0 to 2 were defined as negative expression. Data are expressed as the mean ± SEM (** p < 0.01, *** p < 0.001 versus IR+PBS; n = 7–10).

2.4. The Role of Tregs in the Therapeutic Effects of Bee Venom PLA2 after Radiation-Induced Lung Inflammation

A previous report demonstrated that Treg depletion by an anti-CD25 antibody injection abolished the anti-inflammatory effects of bee venom in asthma, multiple sclerosis, and lupus nephritis [25–27]. Furthermore, it has been confirmed that bvPLA2 induced Tregs from naïve CD4 positive T cells [21] and that Tregs are critical to lung fibrosis [28,29]. To determine whether Tregs were involved in the effects of bvPLA2 on radiation-induced pneumonitis, mice were injected with the PC61 antibody to deplete Treg in vivo. The efficacy of Treg depletion (≥90%) was confirmed prior to irradiation (Figure 5A). The Treg-depleted model system showed a distinct role for Tregs in the effect of bvPLA2 on immune cell infiltration in lung tissue. BvPLA2 treatment showed an obvious effect on the influx of total cells, macrophages, neutrophils, lymphocytes, and eosinophils into BAL fluid in control IgG antibody injected mice. In anti-CD25 antibody-injected mice, however, bvPLA2 showed a tendency to decrease the number of such infiltrated cells, but this was not statistically significant (Figure 5B). These results suggest that Tregs, at least in part, contribute to the therapeutic effects of bvPLA2 in radiation-induced lung inflammation.
3. Discussion

Radiation-induced lung injury is characterized by airway inflammation and occurs in up to 30% of patients who receive irradiation for lung tumor treatment and in approximately 15% of patients with other thoracic cancer, which is now a leading and increasing cause of high morbidity and mortality worldwide [30–32]. The goal of this study was to elucidate the effects of bvPLA2 on IR-induced lung injury. The results of the present study demonstrate that exposure to radiation induces structural changes in terms of inflammation in the lung. In addition, we observed collagen deposition in IR+PBS mice, suggesting an overlap between pneumonitis and fibrosis [33]. The lung tissue of the IR+PBS group showed classical appearances of acute lung injury. By contrast, the bvPLA2-treated group showed less inflammatory cell infiltration in the alveolar space and bronchial lumen.

Bee venom has long been used in alternative medicine to treat a variety of immune-related diseases, such as multiple sclerosis and rheumatoid arthritis, and possesses strong immune modulatory effects [1–6,34,35]. Our recent studies have demonstrated that bvPLA2 possesses a strong capability to increase the population of Tregs and to decrease the inflammatory responses [21,22]. PLA2 is a lipolytic enzyme that produces lysophospholipid and free fatty acids, mainly arachidonic acid, which is a precursor of different bioactive lipid mediators [36]. PLA2 is present in the venoms of snakes, bees, mammals, and scorpions. It has been classified into 15 distinct groups and 4 main types, according to its structure, source, and function [36]. PLA2 derived from bee venom belongs to group III secretory PLA2 [8]. Each PLA2 has an intrinsic function separate to the common function of these enzymes, which causes cleavage of the sn-2 acyl bond of phospholipids. Von Allmen et al. demonstrated that
PLA2-IIId secreted from mouse Tregs promoted the differentiation of Tregs, and inhibited disease development of colitis and multiple sclerosis [37]. For the proper function of bvPLA2, catalytic activity was not required, yet, in our previous study, heat-inactivated bvPLA2 lost its effect for Treg differentiation [21,22]. The observed inflammatory changes were accompanied by an increase in cytokines, such as IL-1β and IL-6, as is observed in pneumonitis, which are associated with impaired lung function [47–53]. In addition, profibrotic cytokines, such as TGF-β and IL-13, contribute to pulmonary fibrosis by promoting the conversion of fibroblasts to myofibroblasts [24,54–56]. Specifically, TGF-β plays an important role in the development of radiation pneumonitis and radiation fibrosis [24]. These cytokines also activate macrophages [55,56]. In the present study, the bvPLA2-treated group showed a suppression of these cytokines and macrophages in lung tissue. Our recent study demonstrated that radiation can injure the cells that activate the NLRP3 inflammasome [33]. The failure to clear the byproducts of cellular damage induced by radiation leads to a hyperactivation of the innate immune system and fibrosis in the lungs [57]. CD4+ T cells abolish macrophage NLRP1 and NLRP3 inflammasome-mediated caspase-1 activation and subsequent interleukin 1β release [58]. CD4+CD25+ Tregs are a subset of the thymus-derived CD4+ T cell population that play a crucial
role in immune regulation by inhibiting the production of cytokines via their constitutive expression of the transcription factor Foxp3 [59,60]. Consistent with these reports, our results show that the NLRP3 inflammasome-related (Nlrp1, Nlrp3, Il-1b, and Casp1) and fibrosis-related (Col3al and Fn1) genes are reduced. These findings suggest that the protective effects of bvPLA2 are associated with the suppressed hyperactivation of the innate immune system.

Taken together, the results of this study suggest that bvPLA2 is an effective target for the regulation of Tregs to significantly ameliorate radiation-induced lung inflammation and fibrosis. BvPLA2 is, as such, a potential candidate for treating radiation-induced inflammation and fibrosis.

4. Materials and Methods

4.1. Irradiation Equipment

Radiation was delivered to a small volume of the left lung, using an image-guided small-animal irradiator, an X-RAD 320 (Precision, North Branford, CT, USA). This irradiator is equipped with a collimator system that is composed of 3.5-cm-thick copper to produce focal radiation beams, an imaging subsystem consisting of a fluorescent screen coupled with a charge-coupled-device camera, and a manually operated stage. The collimators generate a cone beam that ranges from 1 to 7 mm in diameter. The percentage depth doses were measured with GAFCHROMIC EBT2 film [61]. To mimic clinical stereotactic ablative radiotherapy conditions by irradiating only a small tissue volume, we selected 3-mm collimators.

4.2. Mouse Irradiation

All the experiments and animal handling procedures in this study were approved by the Animal Experimental Ethics Committee of the Kyung Hee University and Yonsei University (permit number: 2014-0164-1, approved on 06/26/2014) and performed according to local guidelines. C57BL/6 female mice (6 weeks old, weighing 20–25 g) were purchased from Charles River Korea (Orient Bio, Seongnam, South Korea). The mice were housed (n = 5 in each cage) and allowed to acclimatize for 1 week prior to treatment. A single dose of 75 Gy was delivered to the left lung in a single fraction. In our previous study, we found that a radiation dose of 75 Gy induced inflammation after 3 weeks. The mice were randomly divided into 3 groups (n = 7–10/group): (1) control group: Negative control mice received an intraperitoneal (i.p.) injection of phosphate-buffered saline (PBS) on day 7, 10, 12, 14, 17, and 19; (2) IR+PBS group: Mice were exposed to a single dose of 75 Gy delivered to the left lung in a single fraction and then i.p. injection with PBS on day 7, 10, 12, 14, 17, and 19; (3) bvPLA2 group: Bee venom-derived PLA2 (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in PBS (1 mg/mL) for the stock solution. Stocks were stored −20 °C and diluted with PBS before administration. The mice were administered with bvPLA2 (0.2 mg/kg body weight.) via i.p. injection on day 7, 10, 12, 14, 17, and 19 after IR. During irradiation, the mice were anesthetized with an i.p. administered mixture of 30 mg/kg zoletil and 10 mg/kg rompun. At day 21, mice were sacrificed by CO2 asphyxiation, and lung tissues were collected for analyses. No mice died during the experiment.

4.3. Depletion of CD4+CD25+ Regulatory T Cells In Vivo

Anti-mouse CD25 rat IgG1 (anti-CD25; Clone PC61) was generated in-house from hybridomas obtained from American Type Culture Collection (Manassas, VA, USA). Before irradiation, we confirmed the efficacy of CD4+CD25+ Treg depletion by flow cytometry. We used FOXP3EGFP mice, with PE-anti-mouse CD25 and APC-mouse CD4 antibodies. A single dose of 75 Gy was delivered to the left lung in a single fraction. The C57BL/6 female mice were randomly divided into 7 groups (n = 5/group): (1) control group; (2) IR + PBS group; (3) IR + PBS + total rat IgG group; (4) IR + PBS + PC61 group; (5) IR + bvPLA2 group; (6) IR + bvPLA2 group + total rat IgG group; and (7) IR + bvPLA2 group + PC61 group. A dose of 0.25 mg of the anti-CD25 antibody and total rat IgG was injected on days 0 and 7; (1) control group: Negative control mice received an i.p. injection with PBS alone on days 1, 4,
Toxins 2016, 8, 131

6, 8, 11, and 13; (2) IR + PBS groups: Mice were exposed to a single dose of 75 Gy delivered to the left lung in a single fraction and then i.p. injection with PBS alone on days 1, 4, 6, 8, 11 and 13; (3) bvPLA
2
groups: Mice were administered with bvPLA
2
(0.2 mg/kg body weight.) via i.p. injection on days 1, 4, 6, 8, 11 and 13 after IR. During irradiation, the mice were anesthetized with an i.p. administered mixture of 30 mg/kg zoletil and 10 mg/kg rompun. At day 14, the mice were euthanized using CO2 asphyxiation, and lung tissues were collected for analysis.

4.4. Analysis of Lung Inflammatory Cells

PBS was gradually infused into the lungs and then withdrawn via a cannula that had been inserted into the trachea. This procedure was repeated 3 times, and the lavages were collected. Following this, collected BAL fluid was centrifuged at 1300 rpm for 10 min. The supernatants were stored at −80 °C until further analysis, and the cell pellets were resuspended in 1 mL PBS and adhered to glass slides using cytocentrifugation. The numbers of total and differential cells in the BAL fluid were then determined in a hemocytometer, using trypan blue exclusion. Cells in BAL fluid were distinguished as macrophages, neutrophils, lymphocytes, and eosinophils by Diff-Quick staining [61] In brief, we classify immune cells by size, shape, and color by staining. Eosinophils were stained using Eosin. Macrophages, neutrophils and lymphocytes were stained using hematoxylin. Cells with single, large, round, or indented nuclei were classified as macrophages. Cells with a polymorphonuclear nucleus, with several lobes were sorted as neutrophils. Cells with a clear perinuclear zone around the nucleus were categorized as lymphocytes.

4.5. Preparation of Lung Tissue for Histology and Immunohistochemistry

Lung tissues were fixed in a 4% paraformaldehyde solution and then embedded in paraffin. For histological examination, 4-µm sections of lung tissue were stained sequentially with hematoxylin and eosin (H&E), Masson’s trichrome (MT), and immunohistochemical (IHC) stains. For TGF-β1 detection, lung tissues were treated with 0.3% H2O-methanol for 20 min to block endogenous peroxidase. Subsequently, the sectioned tissues were incubated at 4 °C overnight with an anti-TGF-β1 primary antibody (1:100 dilution; ab64715, Abcam). After the slides were incubated with biotinylated secondary antibody and then with a VECTASTAIN® ABC Reagent (Vector Laboratories, Burlingame, CA, USA), the color was developed with 3,3’-diaminobenzidine tetrachloride (DAB; Zymed Laboratories, San Francisco, CA, USA). After IHC staining, the slides were counterstained with Harris’s hematoxylin for 1 min and then mounted with Canada balsam (Show Chemical Co. Ltd., Tokyo, Japan).

4.6. Histopathology and Immunohistochemistry Scoring

For histopathological evaluation, sections were stained with H&E and MT stains, and scored for the number of inflammatory or fibrotic foci, respectively. For IHC evaluation, sections were stained with TGF-β1 staining. Slides were assessed according to a dual rate semi-quantitative method carried out by 5 independent pathologists who were blinded to the sample data [63]. Randomly selected fields of view for each slide were scored for area and intensity of positively stained (brown) cytoplasm and cell membrane. The intensity scores for positively stained areas were divided into 4 groups: (1) no appreciable staining = 0; (2) barely detectable staining = 1; (3) readily appreciable brown staining = 2; and (4) dark brown staining = 3. The total score was calculated by adding the intensity scores from three independent slides in each sample, resulting in a final score of 0 to 9. For statistical analysis, scores of 3 to 9 were defined as positive expression, while scores of 0 to 2 were defined as negative expression.

4.7. Real-Time Quantitative PCR Analysis

RNA was isolated from lung tissue using an RNeasy Mini Kit (Qiagen, CA, USA) according to the manufacturer’s instructions, and the RNA was quantified using a NanoDrop (ND-1000;
NanoDrop Technologies, Inc., Wilmington, DE, USA). Real-time quantitative PCR was performed using LightCycler 480 SYBR Green I Master mix and a Light Cycler 480 real-time PCR machine (Roche Applied Science, Indianapolis, IN, USA). The expression levels of transcripts were evaluated using Light Cycler 480 software. The transcript levels of β-actin were used for sample normalization. Data were obtained from 3 independent experiments and are represented as average ± standard error. The sequences of the mouse primers were as follows: Nlrp1 (FW 5'-catggctggttcctaccagc-3'; RW 5'-ccaaccacatgtgactctg-3'), Nlrp3 (FW 5'-atgctgcttcgacatctcct-3'; RW 5'-gtttctggaggttgcagagc-3'), Casp1 (FW 5'-cgcacagctggagatggtga-3'; RW 5'-ggtcccacatattccctcct-3'), Il-1b (FW 5'-gcccatcctctgtgactcat-3'; RW 5'-aggccacaggttttgcttcg-3'), Ccl4 (FW 5'-cccacttcctgctgtttctc-3'; RW 5'-gtctgcctcttttggtcagg-3'), Col3a1 (FW 5'-accaaaaggtggctgctccagac-3'; RW 5'-gacctctgcttcagttgacg-3'), Fn1 (FW 5'-acacagctcaacccctcctga-3'; RW 5'-tgtgctctgtgtttgcttc-3'), Il-6 (FW 5'-cggagaggagacttcacag-3'; RW 5'-catcaagctccacccctcctg-3'), Mip1a (FW 5'-atgaaggtctccaccactgc-3'; RW 5'-gatgaattggcgtggaatct-3'), Mcp1 (FW 5'-caatgagtaggctgctccagac-3'; RW 5'-ctggacccattccttcttg-3'), Il-17c (FW 5'-aggtggctgctgtttcagact-3'; RW 5'-catcaagctccacccctcctg-3'), Foxp3 (FW 5'-tcttgccaagctggaagact-3'; RW 5'-ggggttcaaggaagaagagg-3'), and β-actin (FW 5'-gatctggcaccacaccttct-3'; RW 5'-ggggtgttgaaggtctcaaa-3').

4.8. Statistical Analysis

Statistical analysis of the data was conducted using Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). All of the values are presented as the mean ± SEM (standard error of the mean). The statistical significance was assessed by one-way ANOVA followed with Turkey's test with randomly selected samples. A p-value < 0.05 was considered statistically significant.

Acknowledgments: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the the Korea government (MSIP) (NRF-2013R1A2A2A01068954, H.B.; the Nuclear Research and Development Program, NRF-2011-0031695, J.C.) and by the Convergence of Conventional Medicine and Traditional Korean Medicine R&D program funded by the Ministry of Health & Welfare through the Korea Health Industry Development Institute (HI15C0214, J.C. and H.B.).

Author Contributions: J.C. and H.B. conceived and designed the experiments; D.S., S.P., K.-H.J., and J.M.L. performed the experiments; D.S., S.-H.S., and G.L. analyzed the data; J.C., H.B., and J.Y. contributed reagents/materials/analysis tools; D.S. and G.L. wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Rolland, J.; O’Hehir, R. Immunotherapy of allergy: Anergy, deletion, and immune deviation. *Curr. Opin. Immunol.* 1998, 10, 640–645. [CrossRef]

2. Yoon, S.Y.; Kwon, Y.B.; Kim, H.W.; Roh, D.H.; Seo, H.S.; Han, H.J.; Lee, H.J.; Beitz, A.J.; Lee, J.H. Bee venom injection produces a peripheral anti-inflammatory effect by activation of a nitric oxide-dependent spinocereular pathway. *Neurosci. Lett.* 2008, 430, 163–168. [CrossRef] [PubMed]

3. Park, M.H.; Choi, M.S.; Kwak, D.H.; Oh, K.W.; Yoon do, Y.; Han, S.B.; Song, H.S.; Song, M.J.; Hong, J.T. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of nf-kappab. *Prostate* 2011, 71, 801–812. [CrossRef] [PubMed]

4. Cho, S.Y.; Shim, S.R.; Rhee, H.Y.; Park, H.J.; Jung, W.S.; Moon, S.K.; Park, J.M.; Ko, C.N.; Cho, K.H.; Park, S.U. Effectiveness of acupuncture and bee venom acupuncture in idiopathic parkinson’s disease. *Parkinsonism Relat. Disord.* 2012, 18, 948–952. [CrossRef] [PubMed]

5. Mirshafiey, A. Venom therapy in multiple sclerosis. *Neuropharmacology* 2007, 53, 353–361. [CrossRef] [PubMed]

6. Akdis, C.A.; Akdis, M.; Blesken, T.; Wymann, D.; Alkan, S.S.; Muller, U.; Blaser, K. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. *J. Clin. Investig.* 1996, 98, 1676–1683. [CrossRef] [PubMed]

7. Lariviere, W.R.; Melzack, R. The bee venom test: A new tonic-pain test. *Pain* 1996, 66, 271–277. [CrossRef]

8. Lee, G.; Bae, H. Bee venom phospholipase A2: Yesterday’s enemy becomes today’s friend. *Toxins* 2016, 8, 48. [CrossRef] [PubMed]
9. Onishi, H.; Araki, T. Stereotactic body radiation therapy for stage I non-small-cell lung cancer: A historical overview of clinical studies. *Jpn. J. Clin. Oncol.* 2013, 43, 345–350. [CrossRef] [PubMed]

10. Simone, C.B., 2nd; Wildt, B.; Haas, A.R.; Pope, G.; Rengan, R.; Hahn, S.M. Stereotactic body radiation therapy for lung cancer. *Chest* 2013, 143, 1784–1790. [CrossRef] [PubMed]

11. Tsoutsou, P.G.; Koukourakis, M.I. Radiation pneumonitis and fibrosis: Mechanisms underlying its pathogenesis and implications for future research. *Int. J. Radiat. Oncol. Biol. Phys.* 2006, 66, 1281–1293. [CrossRef] [PubMed]

12. Schaue, D.; McBride, W.H. Links between innate immunity and normal tissue radiobiology. *Radiat. Res.* 2010, 173, 406–417. [CrossRef] [PubMed]

13. Marks, L.B.; Yu, X.; Vujaskovic, Z.; Small, W., Jr.; Folz, R.; Anscher, M.S. Radiation-induced lung injury. *Semin. Radiat. Oncol.* 2003, 13, 333–345. [CrossRef]

14. Demaria, S.; Banerjee, S.; Hugunin, M.; Butler, D.; Herzog, L.; Carter, A.; Quintal, L.; Sekut, L.; Talian, R.; Talanian, R.; Talanian, C.; Paskind, M.; et al. Caspase-1 processes IFN-g-induced factor and regulates IFN-g production. *Nature* 1997, 386, 619–623. [CrossRef] [PubMed]

15. Kostura, M.J.; Tocci, M.J.; Limjuco, G.; Chin, J.; Cameron, P.; Hillman, A.G.; Charrain, N.A.; Schmidt, J.A. Identification of a monocyte specific pre-interleukin 1β convertase activity. *Proc. Natl. Acad. Sci. USA* 1989, 86, 5227–5231. [CrossRef] [PubMed]

16. Yang, J.C.; Yang, H.C.; Shun, C.T.; Wang, T.H.; Chien, C.T.; Kao, J.Y. Catechins and sialic acid attenuate helicobacter pylori lipopolysaccharide-stimulated macrophages. *J. Biol. Chem.* 2005, 280, 4279–4288. [CrossRef] [PubMed]

17. Ko, C.N.; Lee, I.W.; Cho, S.Y.; Lee, S.H.; Park, S.U.; Koh, J.S.; Park, J.M.; Kim, G.K.; Bae, H.S. Acupuncture for cerebral vasospasm after subarachnoid hemorrhage: A retrospective case-control study. *J. Altern. Complement. Med.* 2013, 19, 471–473. [CrossRef] [PubMed]

18. Kim, H.; Lee, G.; Park, S.; Chung, H.S.; Kim, J.Y.; Nam, S.; Kim, S.K.; Bae, H. Bee venom phospholipase A2, a novel FOXP3+ regulatory T cell inducer, protects dopaminergic neurons by modulating neuroinflammatory responses in a mouse model of parkinson’s disease. *J. Immunol.* 2015, 195, 4853–4860. [CrossRef] [PubMed]

19. Kim, H.; Lee, G.; Jang, H.; Kim, S.S.; Yoon, H.; Kang, G.H.; Hwang, D.S.; Kim, S.K.; Chung, H.S.; et al. Phospholipase A2 inhibits cisplatin-induced acute kidney injury by modulating regulatory T cells by the CD206 mannose receptor. *Kidney Int.* 2015, 88, 550–559. [CrossRef] [PubMed]

20. Park, S.J.; Baek, H.J.; Jung, K.H.; Lee, G.H.; Lee, H.H.; Kang, G.H.; Lee, G.S.; Bae, H.S. Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin-induced asthma model through the induction of regulatory T cells. *Immun. Inflamm. Dis.* 2015, 3, 386–397. [CrossRef] [PubMed]

21. Anscher, M.S.; Murase, T.; Prescott, D.M.; Marks, L.B.; Reisenbichler, H.; Bentel, G.C.; Spencer, D.; Sherouse, G.; Jirtle, R.L. Changes in plasma TGF β levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. *Int. J. Radiat. Oncol. Biol. Phys.* 1994, 30, 671–676. [CrossRef]

22. Choi, M.S.; Park, S.; Choi, T.; Lee, G.; Haam, K.K.; Hong, M.C.; Min, B.I.; Bae, H. Bee venom ameliorates ovalbumin induced allergic asthma via modulating CD4+CD25+ regulatory T cells in mice. *Cytokine* 2013, 61, 256–265. [CrossRef] [PubMed]

23. Kim, H.; Lee, G.; Park, S.; Chung, H.S.; Lee, H.; Kim, J.Y.; Nam, S.; Kim, S.K.; Bae, H. Bee venom mitigates cisplatin-induced nephrotoxicity by regulating CD4(+)CD25(+)FOXP3(+) regulatory T cells in mice. *Evid. Based Complement. Altern. Med.* 2013, 2013, 879845. [CrossRef] [PubMed]
27. Lee, H.; Lee, E.J.; Kim, H.; Lee, G.; Um, E.J.; Kim, Y.; Lee, B.Y.; Bae, H. Bee venom-associated TH1/TH2 immunoglobulin class switching results in immune tolerance of NZB/W F1 murine lupus nephritis. *Am. J. Nephrol.* 2011, 34, 163–172. [CrossRef] [PubMed]

28. Peng, X.; Moore, M.W.; Peng, H.; Sun, H.; Gan, Y.; Homer, R.J.; Herzog, E.L. CD4+CD25+FOXP3+ regulatory tregs inhibit fibrocyte recruitment and fibrosis via suppression of FGF-9 production in the TGF-β1 exposed murine lung. *Front. Pharmacol.* 2014, 5, 80. [CrossRef] [PubMed]

29. Kotsianidis, I.; Nakou, E.; Bouchliou, I.; Tzouvelekis, A.; Spanoudakis, E.; Steiropoulos, P.; Sotiriou, I.; Aidinis, V.; Margaritis, D.; Tsalas, C.; et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* 2009, 179, 1121–1130. [CrossRef] [PubMed]

30. Sohn, S.H.; Jang, H.; Kim, Y.; Jang, Y.P.; Cho, S.H.; Jung, H.; Jung, S.; Bae, H. The effects of gamijinhae-tang on elastase/lipopolysaccharide-induced lung inflammation in an animal model of acute lung injury. *BMC Complement. Altern. Med.* 2013, 13, 176. [CrossRef] [PubMed]

31. Kelly, P.; Baler, P.A.; Rebuemo, N.; Sharp, H.J.; Liao, Z.; Komaki, R.; Chang, J.Y. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. *Int. J. Radiat. Oncol. Biol. Phys.* 2010, 78, 1387–1393. [CrossRef] [PubMed]

32. Lee, J.C.; Kinniry, P.A.; Arguiri, E.; Serota, M.; Kanterakis, S.; Chatterjee, S.; Solomides, C.C.; Javvadi, P.; Koumenis, C.; Cengel, K.A.; et al. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. *Radiat. Res.* 2010, 173, 590–601. [CrossRef] [PubMed]

33. Sohn, S.H.; Lee, J.M.; Park, S.; Yoo, H.; Kang, J.W.; Shin, D.; Jung, K.H.; Lee, Y.S.; Cho, J.; Bae, H. The inflammasome accelerates radiation-induced lung inflammation and fibrosis in mice. *Environ. Toxicol. Pharmacol.* 2015, 39, 917–926. [CrossRef] [PubMed]

34. Castro, H.J.; Mendez-Lnocencio, J.I.; Omidvar, B.; Omidvar, J.; Santilli, J.; Nielsen, H.S., Jr.; Pavot, A.P.; Richert, J.R.; Bellanti, J.A. A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis. *Allergy Asthma Proc.* 2005, 26, 470–476. [PubMed]

35. Chen, J.; Lariviere, W.R. The nociceptive and anti-nociceptive effects of bee venom injection and therapy: A double-edged sword. *Prog. Neurobiol.* 2010, 92, 151–183. [CrossRef] [PubMed]

36. Burke, J.E.; Dennis, E.A. Phospholipase A2 structure/function, mechanism, and signaling. *J. Lipid Res.* 2009, 50, S237–S242. [CrossRef] [PubMed]

37. Von Allmen, C.E.; Schmitz, N.; Bauer, M.; Hinton, H.J.; Kurrer, M.O.; Brugman, M.H.; Tiemessen, M.M.; Hoogduijn, M.J.; Fibbe, W.E.; Roelofs, H. Prostaglandin E2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. *Stem Cells* 2013, 31, 1980–1991. [CrossRef] [PubMed]

38. Annand, R.R.; Kontoyianni, M.; Penzotzi, J.E.; Dudler, T.; Lybrand, T.P.; Gelb, M.H. Active site of bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. *Stem Cells* 2013, 31, 1980–1991. [CrossRef] [PubMed]

39. Palm, N.W.; Rosenstein, R.K.; Yu, S.; Schenten, D.D.; Florsheim, E.; Medzhitov, R. Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. *Proc. Natl. Acad. Sci. USA* 2009, 106, 17910–17915. [CrossRef] [PubMed]

40. Sultani, M.; Stringer, A.M.; Bowen, J.M.; Gibson, R.J. Anti-inflammatory cytokines: Important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. *Chemother Res. Pract.* 2012, 2012, 490804. [CrossRef] [PubMed]

41. Baratelli, F.; Lin, Y.; Zhu, L.; Yang, S.C.; Heuze-Vourc’h, N.; Zeng, G.; Reckamp, K.; Dubadwala, M.; Sharma, S.; Dubinett, S.M. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. *J. Immunol.* 2005, 175, 1483–1490. [CrossRef] [PubMed]

42. Melief, S.M.; Schrama, E.; Brugman, M.H.; Tiemessen, M.M.; Hoogduijn, M.J.; Fibbe, W.E.; Roelofs, H. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. *Stem Cells* 2013, 31, 1980–1991. [CrossRef] [PubMed]

43. Pommer, A.; Audemard, A.; Durand, A.; Lengagne, R.; Delpoux, A.; Martin, B.; Douguet, L.; Le Campion, A.; Kato, M.; Avril, M.F.; et al. Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells. *Proc. Natl. Acad. Sci. USA* 2013, 110, 13085–13090. [CrossRef] [PubMed]

44. Li, J.; Qiu, S.J.; She, W.M.; Wang, F.P.; Gao, H.; Li, L.; Tu, C.T.; Wang, J.Y.; Shen, X.Z.; Jiang, W. Significance of the balance between regulatory T (TREG) and T helper 17 (TH17) cells during hepatitis B virus related liver fibrosis. *PLoS ONE* 2012, 7, e39307. [CrossRef] [PubMed]
45. Insel, P.A.; Murray, F.; Yokoyama, U.; Romano, S.; Yun, H.; Brown, L.; Snead, A.; Lu, D.; Aroonsakool, N. Camp and EPAC in the regulation of tissue fibrosis. Br. J. Pharmacol. 2012, 166, 447–456. [CrossRef] [PubMed]
46. Lovgren, A.K.; Jania, L.A.; Hartney, J.M.; Parsons, K.K.; Audoly, L.P.; Fitzgerald, G.A.; Tilley, S.L.; Koller, B.H. Cox-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2006, 291, L144–L156. [CrossRef] [PubMed]
47. Hasegawa, M.; Fujimoto, M.; Takehara, K.; Sato, S. Pathogenesis of systemic sclerosis: Altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J. Dermatol. Sci. 2005, 39, 1–7. [CrossRef] [PubMed]
48. De Torres, J.P.; Pinto-Plata, V.; Casanova, C.; Mullerova, H.; Cordoba-Lanus, E.; Muros de Fuentes, M.; Aguirre-Jaime, A.; Celli, B.R. C-reactive protein levels and survival in patients with moderate to very severe copd. Chest 2008, 133, 1336–1343. [CrossRef] [PubMed]
49. Hurst, J.R.; Donaldson, G.C.; Perera, W.R.; Wilkinson, T.M.; Bilello, J.A.; Hagan, G.W.; Vessey, R.S.; Wedzicha, J.A. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006, 174, 867–874. [CrossRef] [PubMed]
50. Hurst, J.R.; Perera, W.R.; Wilkinson, T.M.; Donaldson, G.C.; Wedzicha, J.A. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006, 173, 71–78. [CrossRef]
51. Wilkinson, T.M.; Hurst, J.R.; Perera, W.R.; Wilks, M.; Donaldson, G.C.; Wedzicha, J.A. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of copd. Chest 2006, 129, 317–324. [CrossRef] [PubMed]
52. Yende, S.; Waterer, G.W.; Tolley, E.A.; Newman, A.B.; Bauer, D.C.; Taaffe, D.R.; Jensen, R.; Crapo, R.; Rubin, S.; Nevitt, M.; et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006, 61, 10–16. [CrossRef] [PubMed]
53. Kuhn, C., 3rd; Homer, R.J.; Zhu, Z.; Ward, N.; Flavell, R.A.; Geba, G.P.; Elias, J.A. Airway hyperresponsiveness and airway obstruction in transgenic mice. Morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung. Am. J. Respir. Cell Mol. Biol. 2000, 22, 289–295. [CrossRef]
54. Graves, P.R.; Siddiqui, F.; Anscher, M.S.; Movsas, B. Radiation pulmonary toxicity: From mechanisms to management. Semin. Radiat. Oncol. 2010, 20, 201–207. [CrossRef] [PubMed]
55. Li, M.O.; Wan, Y.Y.; Sanjabi, S.; Robertson, A.K.; Flavell, R.A. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 2006, 24, 99–146. [CrossRef] [PubMed]
56. Wynn, T.A. IL-13 effector functions. Annu. Rev. Immunol. 2003, 21, 425–456. [CrossRef] [PubMed]
57. Meneghin, A.; Hogaboam, C.M. Infectious disease, the innate immune response, and fibrosis. J. Clin. Investig. 2007, 117, 530–538. [CrossRef] [PubMed]
58. Guarda, G.; Dostert, C.; Staeuhl, F.; Cabalzar, K.; Castillo, R.; Tardivel, A.; Schneider, P.; Tschopp, J. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 2009, 460, 269–273. [CrossRef] [PubMed]
59. Powrie, F.; Coffman, R.L.; Correa-Oliveira, R. Transfer of CD4+ T cells to C.B-17 scid mice: A model to study th1 and TH2 cell differentiation and regulation in vivo. Res. Immunol. 1994, 145, 347–353. [CrossRef]
60. Horii, S.; Takahashi, T.; Sakaguchi, S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv. Immunol. 2003, 81, 331–371. [PubMed]
61. Hong, Z.Y.; Eun, S.H.; Park, K.; Choi, W.H.; Lee, J.I.; Lee, E.J.; Lee, J.M.; Story, M.D.; Cho, J. Development of a small animal model to simulate clinical stereotactic body radiotherapy-induced central and peripheral lung injuries. J. Radiat. Res. 2014, 55, 648–657. [CrossRef] [PubMed]
62. Meyer, K.C.; Raghu, G.; Baughman, R.P.; Brown, K.K.; Costabel, U.; du Bois, R.M.; Drent, M.; Haslam, P.L.; Kim, D.S.; Nagai, S.; et al. An official american thoracic society clinical practice guideline: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit. Care Med. 2012, 185, 1004–1014. [CrossRef] [PubMed]
63. Dhillon, T.; Mauri, F.A.; Bellezza, G.; Cagini, L.; Barbaresci, M.; North, B.V.; Seckl, M.J. Overexpression of the mammalian target of rapamycin: A novel biomarker for poor survival in resected early stage non-small cell lung cancer. J. Thorac. Oncol. 2010, 5, 314–319. [CrossRef] [PubMed]